WEBINAR RECORDING AVAILABLE - WATCH ON DEMAND

DEL like never before - 4th generation of DEL kits

Self-service DNA Encoded library (DEL) kits are a core component of the Target-to-Hit platform at WuXi AppTec HitS. DELopen is a freely accessible collection of DELs for academic drug discovery, while DELight allows pharmaceutical companies to conduct a DEL screen in their own lab, without needing to reveal the identity of their target. Three years after the initial launch, the 4^th generation of DEL kits are ready to be released. The updated DELight kits contain new features packed in one box: improved drug-like space, frequency hitter index, 5-min QC, and other bonuses coming together.

WHO SHOULD ATTEND THIS WEBINAR

Academics interested in screening their (protein/biomolecule) targets for drug-like chemical matter using freely accessible DELs.
Industry scientists interested in conducting DEL screens without revealing target identity and/or developing proprietary screening techniques in their own labs.

WHAT WILL BE COVERED IN THIS WEBINAR

The basics of how the DEL kit works
New features of 4^th generation of the DEL kit
Successful stories using the DEL kit

watch now

Alex Satz

Senior director of DEL strategy and operations, WuXi AppTec

Dr. Alex Satz has 15+ years of experience building and leading DNA encoded library (DEL) technology platforms, and is currently the senior director of DEL strategy and operations at WuXi AppTec. Prior to joining WuXi AppTec, Alex built and led the Roche DEL platform in Basel Switzerland and Nutley USA, and helped to develop the first industrial-scale DEL platform at Praecis Pharmaceuticals (later purchased by GlaxoSmithKline). Alex also worked as a medicinal chemist at AstraZeneca, was an NIH postdoctoral fellow at Harvard Medical School, and earned his PhD in organic chemistry from the University of California Santa Barbara. In the field of DEL, Alex has authored 18 peer-reviewed articles and two book chapters.

Habil Nuska Tschammer

Head of DEL Lab Operations Europe, WuXi AppTec

Dr. Habil Nuska Tschammer is Head of DEL Lab Operations at WuXi AppTec´s HitS/Crelux in Munich, Germany. Prior to this role, she was Subject Matter Expert at Crelux. Before that, she was Head of Research and Development Biochemistry at NanoTemper Technologies, where she developed a new generation of dyes for the MicroScale Thermophoresis (MST) and Dianthus (TRIC). During the habilitation in Medicinal Chemistry at Friedrich-Alexander University, Erlangen, Germany, her research on the allosteric modulation of GPRCs was funded by several grants of German Research Foundation (DFG), which led to many publications and patents. She received various prizes and awards, among them Innovation Award in Medicinal Chemistry, which is jointly awarded by Society of German Chemists (GDCh) and German Pharmaceutical Society (DPhG).

Ken Westover

Assoc. Prof. Biochemistry and Radiation Oncology, Director of Clinical Innovation, UT Southwestern

Dr. Westover began his research career at UT Southwestern as a Summer Undergraduate Research Fellow in the labs of Michael Brown and Joseph Goldstein, studying small GTPases. Their passion for merging high-quality basic and medical science inspired him to become a physician-scientist. As an undergraduate Dr. Westover studied COX2 inhibitors such as celecoxib and rofecoxib and from that developed an interest in structural biology and computer-aided drug design. He later graduated from the Medical Scientist Training Program at Stanford University, where he studied the structural biology of RNA polymerase II in the lab of Roger Kornberg. Dr. Westover completed medical residency training in the Harvard Radiation Oncology Program. During training, he worked in the lab of Nathanael Gray in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical as a Holman Research Pathway Fellow (American Board of Radiology). At that time, he initiated a KRAS G12C inhibitor program.

Dr. Westover established his own laboratory at UTSW in 2012 with the assistance of a CPRIT grant to continue work on KRAS G12C inhibitors and kinase inhibitors. The Westover lab also has research programs to how specific RAS mutations differ in their cancer-causing mechanisms, with an emphasis on targeting additional RAS forms with small molecules for therapeutic purposes.

moderator

Arsalan Arif

Founder & Publisher, Endpoints News

Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.